You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

HYTRIN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Hytrin, and when can generic versions of Hytrin launch?

Hytrin is a drug marketed by Abbott and is included in two NDAs.

The generic ingredient in HYTRIN is terazosin hydrochloride. There are twenty-four drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the terazosin hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Hytrin

A generic version of HYTRIN was approved as terazosin hydrochloride by APNAR PHARMA LP on March 30th, 1998.

  Try a Trial

Drug patent expirations by year for HYTRIN
Recent Clinical Trials for HYTRIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Michael J. Fox Foundation for Parkinson's ResearchPhase 1
University of IowaPhase 1
University of IowaPhase 1/Phase 2

See all HYTRIN clinical trials

US Patents and Regulatory Information for HYTRIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbott HYTRIN terazosin hydrochloride CAPSULE;ORAL 020347-001 Dec 14, 1994 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Abbott HYTRIN terazosin hydrochloride TABLET;ORAL 019057-003 Aug 7, 1987 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Abbott HYTRIN terazosin hydrochloride CAPSULE;ORAL 020347-004 Dec 14, 1994 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Abbott HYTRIN terazosin hydrochloride TABLET;ORAL 019057-004 Aug 7, 1987 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Abbott HYTRIN terazosin hydrochloride CAPSULE;ORAL 020347-002 Dec 14, 1994 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for HYTRIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbott HYTRIN terazosin hydrochloride CAPSULE;ORAL 020347-004 Dec 14, 1994 ⤷  Try a Trial ⤷  Try a Trial
Abbott HYTRIN terazosin hydrochloride TABLET;ORAL 019057-001 Aug 7, 1987 ⤷  Try a Trial ⤷  Try a Trial
Abbott HYTRIN terazosin hydrochloride TABLET;ORAL 019057-004 Aug 7, 1987 ⤷  Try a Trial ⤷  Try a Trial
Abbott HYTRIN terazosin hydrochloride TABLET;ORAL 019057-003 Aug 7, 1987 ⤷  Try a Trial ⤷  Try a Trial
Abbott HYTRIN terazosin hydrochloride CAPSULE;ORAL 020347-003 Dec 14, 1994 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for HYTRIN

See the table below for patents covering HYTRIN around the world.

Country Patent Number Title Estimated Expiration
Philippines 15619 1-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-4-(2-TETRAHYDROFUROYL)PIPERAZINE HYDROCHLORIDE DIHYDRATE ⤷  Try a Trial
Ireland 72967 R(+)-Terazosin ⤷  Try a Trial
Japan 2711230 ⤷  Try a Trial
Denmark 0536329 ⤷  Try a Trial
Greece 3021319 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.